Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease

Annals of the Rheumatic Diseases

Volumn 63, Issue 11, 2004, Pages 1445-1449

  Leiba, M ^a   Seligsohn, U ^a   Sidi, Y ^a   Harats, D ^a   Sela, B A ^a   Griffin, J H ^b   Livneh, A ^a   Rosenberg, N ^a   Gelernter, I ^c   Gur, H ^a   Ehrenfeld, M ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN B100; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; AZATHIOPRINE; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; COLCHICINE; CORTICOSTEROID; CYCLOOXYGENASE 2; CYCLOSPORIN A; GLUCOSYLCERAMIDE; HOMOCYSTEINE; INTERSTITIAL COLLAGENASE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN ADAMTS 4; PROTHROMBIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BEHCET DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DYSLIPIDEMIA; FEMALE; GENETIC POLYMORPHISM; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; STATISTICAL ANALYSIS; THROMBOPHILIA; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; APOLIPOPROTEINS; BEHCET SYNDROME; BIOLOGICAL MARKERS; CHILD; CHOLESTEROL; CHOLESTEROL, VLDL; FACTOR VIII; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREVALENCE; THROMBOPHILIA; THROMBOSIS; TRIGLYCERIDES;

EID: 7244229643     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.014241     Document Type: Article

References (24)

1. Sakane T, Takeno M, Suzuki N, Inabo G. Behcet's disease. N Engl J Med 1999;341:1284-91.
2. Gul A, Ozbek U, Ozturk C, Inanc M, Konice M, Ozcelik T. Coagulation factor V gene mutation increases the risk of venous thrombosis in Behcet's disease. Br J Rheumatol 1996;35:1178-80.
3. Kuzu MA, Ozaslan C, Koksoy C, Gurler A, Tuzuner A. Vascular involvement in Behcet's disease: 8 year audit. World J Surg 1994;18:948-54.
4. Leiba M, Sidi Y, Gur H, Leibo A, Ehernfeld M. Behcet's disease and thrombophilia. Ann Rheum Dis 2001;60:1081-5.
5. Ozatli D, Sayinalp N, Buyukasik Y, Karakus S, Haznedaroglu IC, Kirazli S, et al. Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behcet's disease: evidence of a prethrombotic state. Rheumatol Int 2002;21:137-40.
6. Kiraz S, Ertenli I, Ozturk MA, Haznedaroglu IC, Celik I, Calguneri M. Pathological haemostasis and "prothrombotic state" in Behcet's disease. Thromb Res 2002;105:125-33.
7. Deguchi H, Fernandez JA, Pabinger I, Heit JA, Griffin JH. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood 2001;97:1907-14.
8. Wechsler B, Davatchi F, Hamza M, Dilsen N, Kansu E, et al. Criteria for diagnosis of Behcet's disease - International Study Group for Behcet's disease. Lancet 1990;335:1078-80.
9. Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999;19:511-18.
10. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobolamin and folate concentrations in healthy subjects. Clin Chem 1994;40:873-81.
11. Rifai N, Silverman LM. Immunoturbidimetric techniques for quantifying apolipoproteins CII and CIII. Clin Chem 1986;32:1969-72.
12. Noma A, Hata Y, Goto Y. Quantitation of serum apalipaprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values, and age- and sex-related differences. Clin Chim Acta 1991;199:147-57.
13. Ehrlich GE. Vasculitis in Behcet's disease. Int Rev Immunol 1997;14:81-8.
14. Toydemir PB, Elhan AH, Tukun A, Toydemir R, Gurler A Tuzuner A, et al. Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous lhrombogenesis in Behcet's disease. J Rheumatol 2000;27:2849-54.
15. Siliagardi M, Ghirarduzzi A, Iori I, Salvarani C, Boiardi L, Bellesia E, et al. Factor V Leiden and G20210A prothrombin alleles are not associated with thrombosis in Behcet's disease [abstract]. Thromb Haemost 2001;85(suppl):2519.
16. Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, Lopez-Soto A, et al. Vascular involvement in Behcet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002;112:37-43.
17. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-5.
18. Vaya A, Mira Y, Fernando F, Contreras M, Estelles A, Espana F, et al. Hyperlipidemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002;118:255-9.
19. Kawasaki T, Kamboyashi J, Ariyoshi H, Sakon M, Suehisa E, Monden M. Hypercholesterolemia as a risk factor for deep-vein thrombosis. Thromb Res 1997;88:67-73.
20. von Depka M, Nowak-Gottl U, Eisert R, Dieterich C, Barthels M, Scharrer I, et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000;96:3364-8.
21. Griffin JH, Fernandez JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 2001;86:386-94.
22. Moyer MP, Tracy RP, Tracy PB, van't Veer C, Sparks CE, Mann KG. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol 1998;18:458-65.
23. Kjalke M, Silveira A, Hamsten A, Hedner U, Ezban M. Plasma lipoproteins enhance tissue factor-independent factor VII activation. Arterioscler Thromb Vasc Biol 2000;20:1835-41.
24. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001;161:1405-10.